S. Shahidi-Latham

发表

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma

Adam R. Johnson, N. C. Ray, G. Cain, 2018, Science Translational Medicine.

Feasibility Assessment of a MALDI FTICR Imaging Approach for the 3D Reconstruction of a Mouse Lung

S. Shahidi-Latham, E. E. Jones, Cristine Quiason, 2017, Journal of The American Society for Mass Spectrometry.

DMD057513 1110..1116

H. Phillips, R. Carano, B. Alicke, 2014 .

Imaging MALDI MS of Dosed Brain Tissues Utilizing an Alternative Analyte Pre-extraction Approach

S. Shahidi-Latham, Cristine Quiason, 2015, Journal of The American Society for Mass Spectrometry.

Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947

J. Lubach, Xingrong Liu, C. Hop, 2020, Drug Metabolism and Disposition.

Structure of the essential inner membrane lipopolysaccharide–PbgA complex

Benjamin D. Sellers, M. Hunter, D. DePonte, 2020, Nature.

A rapid derivatization based LC-MS/MS method for quantitation of short chain fatty acids in human plasma and urine.

S. Shahidi-Latham, Dewakar Sangaraju, Allan Jaochico, 2019, Bioanalysis.

Evaluation of homogenization techniques for the preparation of mouse tissue samples to support drug discovery.

B. Liederer, Xiaorong Liang, S. Shahidi-Latham, 2011, Bioanalysis.

Charkoftaki, Georgia and Rattray, Nicholas J. W. and Andrén, Per E. and Caprioli, Richard M. and Castellino, Steven and Duncan, Mark W. and Goodwin, Richard J. A. and Schey, Kevin L. and Shahidi-Latham, Sheerin

Caroline H. Johnson, R. Caprioli, K. Veselkov, 2019 .

Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947

J. Lubach, Xingrong Liu, C. Hop, 2020, Drug Metabolism and Disposition.

Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.

J. Blake, Jianping Yin, Weiru Wang, 2015, Journal of medicinal chemistry.

Tissue Localization of Glycosphingolipid Accumulation in a Gaucher Disease Mouse Brain by LC-ESI-MS/MS and High-Resolution MALDI Imaging Mass Spectrometry

Ying Sun, K. Setchell, R. Drake, 2017, SLAS discovery : advancing life sciences R & D.

Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma

L. Rangell, H. Phillips, H. Koeppen, 2016, Drug Metabolism and Disposition.

Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models—Assessment by Matrix-Assisted Laser Desorption Ionization Imaging

H. Phillips, R. Carano, B. Alicke, 2014, Drug Metabolism and Disposition.

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle

Greg M. Thurber, A. Iagaru, D. Wolf, 2018, Clinical pharmacology and therapeutics.

Collagenase as an effective tool for drug quantitation in tissues.

Ann Qin, S. Shahidi-Latham, B. Dean, 2015, Bioanalysis.

Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.

J. Chan, E. Choo, E. Plise, 2014, Molecular pharmaceutics.

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.

J. Blake, Jianping Yin, Weiru Wang, 2014, Bioorganic & medicinal chemistry letters.

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

Lily Shao, Mark Merchant, Eva Lin, 2017, PloS one.

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

M. Belvin, D. Kirouac, H. Koeppen, 2018, PloS one.

Yale School of Public Health Symposium on tissue imaging mass spectrometry: illuminating phenotypic heterogeneity and drug disposition at the molecular level

Caroline H. Johnson, R. Caprioli, K. Veselkov, 2018, Human Genomics.

Evaluation of an accurate mass approach for the simultaneous detection of drug and metabolite distributions via whole-body mass spectrometric imaging.

Maria C Prieto Conaway, S. Shahidi-Latham, P. Rudewicz, 2012, Analytical chemistry.

Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development

S. Gould, M. Belvin, Peter Yin, 2014 .

Characterization of Anti-Neovascularization Activity and Ocular Pharmacokinetics of PI3K/mTOR Inhibitor GNE-947

C. Hop, S. Shahidi-Latham, J. Nonomiya, 2020 .

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle

Greg M. Thurber, A. Iagaru, D. Wolf, 2018, Clinical pharmacology and therapeutics.

A multi‐matrix HILIC‐MS/MS method for the quantitation of endogenous small molecule neurological biomarker N‐acetyl aspartic acid (NAA)

S. Shahidi-Latham, B. Dean, Dewakar Sangaraju, 2017, Journal of pharmaceutical and biomedical analysis.

Identification and Distribution of a Reserpine Metabolite in Dosed Whole-body Rat Tissue using MS and MS/MS Mass Spectrometric Imaging

S. Shahidi-Latham, P. Pribil, 2010 .